Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers Webinar Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers CertaraMarch 9, 2026
Navigate GxP Compliance in the Cloud with Confidence Guide Navigate GxP Compliance in the Cloud with Confidence Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…CertaraMarch 6, 2026
ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success Blog ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…CertaraMarch 3, 2026
Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development Conference Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development Danielle PillsburyMarch 2, 2026
Phoenix Roadshow 2026 – Raleigh/Durham Live Events Phoenix Roadshow 2026 – Raleigh/Durham CertaraMarch 2, 2026
Phoenix Roadshow 2026 – Radnor (Philadelphia area) Live Events Phoenix Roadshow 2026 – Radnor (Philadelphia area) CertaraFebruary 27, 2026
Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit) On-Demand Webinar Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit) This webinar introduces the Phoenix IVIVC Toolkit, showing how to perform BE analysis and build…CertaraFebruary 27, 2026
Blog Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…CertaraFebruary 26, 2026
Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Webinar Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Danielle PillsburyFebruary 23, 2026